USV Launches INSUQUICK, First Biosimilar Insulin Aspart in India
USV Pvt. Ltd, leaders in oral anti-diabetes segment, has announced the launch of 1st biosimilar Insulin Aspart in India, INSUQUICK, for the treatment of people living with Diabetes
INSUQUICK® is DCGI-approved for the management of glycemic control in people living with Diabetes.
INSUQUICK® is available in INSUQUICK® Cartridge, INSUQUICK® vial & INSUQUICK® VDPen.
INSUQUICK® VDPen is a prefilled, disposable variable dose pen injector, featuring a modern robust design, lightweight, large legible scale, and with audible clicks for precise incremental settings.
USV has also announced the launch of USVPen®, a reusable pen designed for USV’s range of insulin. USVPen® delivers accurate dose of insulin with low dose force which makes it user-friendly.
Achieved through relentless R&D efforts of more than 10 years, INSUQUICK® uses 100% indigenous robust technology, guaranteeing complete cold chain care. INSUQUICK® aligns with global regulatory standards, making it a world-class and truly "Made in India" affordable solution.
Insuquick establishes fingerprint-like similarity in efficacy, safety, and immunogenicity profile as compared to Innovator.
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)